GVB Biopharma, developer, manufacturer and global distributor of hemp-derived cannabinoid products, has launched CBT Isolate. 

CBT, also known as cannabicitran, is a rare cannabinoid that demonstrates distinct properties and potential benefits. With rigorous in-house testing and a commitment to quality assurance, GVB Biopharma's CBT Isolate is ideal for use in tinctures, topicals, edibles and more.

"Our introduction of CBT Isolate underscores our dedication to leading the industry in both quality and innovation," said Drew Spiegel, CEO of GVB Biopharma. "Rare cannabinoids are at the forefront of new product development, and GVB Biopharma strives to give our customers the best-in-class, high-purity ingredients they need to create differentiated and effective formulations."